Nasdaq Gains 50 Points; US New Home Sales Rise In February
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 25 2025
0mins
Source: Benzinga
U.S. Stock Market Performance: U.S. stocks showed mixed results with the Nasdaq gaining 0.29% while the Dow fell slightly by 0.06%. Notable stock movements included Tenon Medical's shares surging 287% and Mural Oncology's shares dropping 58%.
Economic Indicators: Sales of new single-family homes rose by 1.8% in February, despite a previous decline, while home price indices showed slight increases year-over-year, indicating ongoing fluctuations in the housing market.
Analyst Views on CRMD
Wall Street analysts forecast CRMD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRMD is 18.40 USD with a low forecast of 14.00 USD and a high forecast of 22.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
7 Buy
0 Hold
0 Sell
Strong Buy
Current: 7.010
Low
14.00
Averages
18.40
High
22.00
Current: 7.010
Low
14.00
Averages
18.40
High
22.00
About CRMD
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product, DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 milligrams per milliliter (mg/mL), and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). The Company is also commercializing a portfolio of anti-infective products including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, and KIMYRSA, as well as TOPROL-XL.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
